Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has not paid the principal (in the amount of C$453,000) and interest (in the amount of C$19,323.96) owing on its 9% secured convertible...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that, in accordance with the previously announced agreement between the Company and the former shareholders of the Company’s subsidiary, Talent Biotechs Ltd., the Company has...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the third quarter of 2019. (All dollars U.S. unless otherwise noted.) Third Quarter Financial Results In Q3 2019, the Company had no...
Read More
New Research Adds Evidence Regarding Potential Activity of CBD in Prevention and Treatment of GVHD Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that research reported in two peer-reviewed articles published in Blood...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce that it has closed an additional and final tranche of its private placement, for 2,811,111 common shares of the Company and 2,811,111 common...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce that it has closed an additional tranche of its private placement, for 1,974,445 common shares of the Company and 1,974,445 common share purchase...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") has announced that, due to a decline in the market price for CBD isolate, it has decided not to proceed with its previously announced plan to acquire...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") is pleased to announce that the European Patent Office has issued a Notice of Allowance for EU Patent Application Number 14791611.8 covering the use of cannabidiol (“CBD”)...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce the closing of the first tranche of its private placement, for 10,946,423 common shares of the Company and 10,946,423 common share purchase warrants...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it is updating the terms of its private placement previously announced on August 21, 2019 (the “Private Placement”). The Company proposes to raise up...
Read More